✦ LIBER ✦

PCN73 Economic Analysis of the Use of Crizotinib, a Tyrosine Kinase ALK Inhibitor, in the Treatment of ALK Positive Non-Small Cell Lung Cancer in the Mexican Setting

✍ Scribed by J.G. Gay-Molina; R. Sánchez-Kobashi; E. Muciño-Ortega; C.I. Gutiérrez-Colín; R.M. Galindo-Suárez

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug-induced reduction in estimated glom

✍ Brosnan, Evelyn M.; Weickhardt, Andrew J.; Lu, Xian; Maxon, Delee A.; Barón, Ann 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 520 KB

Crizotinib: A Review of Its Use in the T

✍ Frampton, James E. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 517 KB

369 Timing of responses to crizotinib (P

✍ B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Activity and safety of crizotinib in pat

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB

Cost-Effectiveness of EML4-ALK Fusion Te

✍ Djalalov, S.; Beca, J.; Hoch, J.S.; Krahn, M.D.; Tsao, M.S.; Cutz, J.C.; Leighl, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Effect of crizotinib on overall survival

✍ Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; J 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 250 KB